Literature DB >> 23974647

Diffusion tensor imaging and correlations to Parkinson rating scales.

Niklas Lenfeldt1, William Hansson, Anne Larsson, Lars Nyberg, Richard Birgander, Lars Forsgren.   

Abstract

The contribution of various brain areas to the overall progression of Parkinson's disease remains to be determined. In this study, we apply MRI diffusion tensor imaging to investigate how alterations in diffusion relate to phenotype and symptoms measured by clinical rating scales. Sixty-four patients were investigated at baseline and three follow-ups (1, 3 and 5 years). Thirty-six patients remained in the last follow-up. Regions of interests included frontal white matter, basal ganglia, thalamus, and cerebellum. Scoring on the Unified Parkinson's Disease Rating Scale (UPDRS) I, II, III, Hoehn and Yahr (HY) scale and the Schwab and England scale (SE) was determined. Mean, radial, and axial diffusion and fractional anisotropy were modeled with phenotype and clinical scales in a multivariate/univariate analysis correcting for other covariates. Significance was set at 0.05 Bonferroni corrected. All rating scales except UPDRS III significantly correlated to the diffusion measures, as did clinical phenotype. Specifically, putamen, globus pallidus, and thalamus demonstrated higher diffusion with worsening scores. Diffusion in thalamus was higher in the tremor dominant phenotype than in postural imbalance and gait disturbance. Decline in overall functionality (UPDRS II and SE scale), including mental status (UPDRS I) and stage of the disease (HY scale), in Parkinson's disease is related to altered diffusion in the lentiform nucleus and thalamus. Motor function is not mirrored in diffusion changes, possibly due to medication. Tremor dominant PD patients show diffusion alterations in the thalamus, but the significance of this for tremor generation remains to be determined.

Entities:  

Mesh:

Year:  2013        PMID: 23974647     DOI: 10.1007/s00415-013-7080-2

Source DB:  PubMed          Journal:  J Neurol        ISSN: 0340-5354            Impact factor:   4.849


  56 in total

1.  Movement Disorder Society Task Force report on the Hoehn and Yahr staging scale: status and recommendations.

Authors:  Christopher G Goetz; Werner Poewe; Olivier Rascol; Cristina Sampaio; Glenn T Stebbins; Carl Counsell; Nir Giladi; Robert G Holloway; Charity G Moore; Gregor K Wenning; Melvin D Yahr; Lisa Seidl
Journal:  Mov Disord       Date:  2004-09       Impact factor: 10.338

Review 2.  Advances in functional and structural MR image analysis and implementation as FSL.

Authors:  Stephen M Smith; Mark Jenkinson; Mark W Woolrich; Christian F Beckmann; Timothy E J Behrens; Heidi Johansen-Berg; Peter R Bannister; Marilena De Luca; Ivana Drobnjak; David E Flitney; Rami K Niazy; James Saunders; John Vickers; Yongyue Zhang; Nicola De Stefano; J Michael Brady; Paul M Matthews
Journal:  Neuroimage       Date:  2004       Impact factor: 6.556

3.  Bayesian analysis of neuroimaging data in FSL.

Authors:  Mark W Woolrich; Saad Jbabdi; Brian Patenaude; Michael Chappell; Salima Makni; Timothy Behrens; Christian Beckmann; Mark Jenkinson; Stephen M Smith
Journal:  Neuroimage       Date:  2008-11-13       Impact factor: 6.556

4.  Diffusion tensor imaging in a rat model of Parkinson's disease after lesioning of the nigrostriatal tract.

Authors:  Nadja Van Camp; Ines Blockx; Marleen Verhoye; Cindy Casteels; Frea Coun; Alexander Leemans; Jan Sijbers; Veerle Baekelandt; Koen Van Laere; Annemie Van der Linden
Journal:  NMR Biomed       Date:  2009-08       Impact factor: 4.044

5.  Leucoaraiosis, nigrostriatal denervation and motor symptoms in Parkinson's disease.

Authors:  Nicolaas I Bohnen; Martijn L T M Müller; Natalia Zarzhevsky; Robert A Koeppe; Christopher W Bogan; Michael R Kilbourn; Kirk A Frey; Roger L Albin
Journal:  Brain       Date:  2011-06-08       Impact factor: 13.501

6.  Parkinsonism: onset, progression and mortality.

Authors:  M M Hoehn; M D Yahr
Journal:  Neurology       Date:  1967-05       Impact factor: 9.910

7.  Accuracy of clinical diagnosis of idiopathic Parkinson's disease: a clinico-pathological study of 100 cases.

Authors:  A J Hughes; S E Daniel; L Kilford; A J Lees
Journal:  J Neurol Neurosurg Psychiatry       Date:  1992-03       Impact factor: 10.154

8.  Which clinical sign of Parkinson's disease best reflects the nigrostriatal lesion?

Authors:  F J Vingerhoets; M Schulzer; D B Calne; B J Snow
Journal:  Ann Neurol       Date:  1997-01       Impact factor: 10.422

9.  Case control study of diffusion tensor imaging in Parkinson's disease.

Authors:  L-L Chan; H Rumpel; K Yap; E Lee; H-V Loo; G-L Ho; S Fook-Chong; Y Yuen; E-K Tan
Journal:  J Neurol Neurosurg Psychiatry       Date:  2007-07-05       Impact factor: 10.154

Review 10.  Cerebral causes and consequences of parkinsonian resting tremor: a tale of two circuits?

Authors:  Rick C Helmich; Mark Hallett; Günther Deuschl; Ivan Toni; Bastiaan R Bloem
Journal:  Brain       Date:  2012-03-01       Impact factor: 13.501

View more
  15 in total

1.  Lateralized microstructural changes in early-stage Parkinson's disease in anterior olfactory structures, but not in substantia nigra.

Authors:  N Joshi; T M Rolheiser; J D Fisk; J R McKelvey; K Schoffer; G Phillips; M Armstrong; M N Khan; R A Leslie; B Rusak; H A Robertson; K P Good
Journal:  J Neurol       Date:  2017-06-26       Impact factor: 4.849

Review 2.  Cerebellar Microstructural Abnormalities in Parkinson's Disease: a Systematic Review of Diffusion Tensor Imaging Studies.

Authors:  Maryam Haghshomar; Parnian Shobeiri; Seyed Arsalan Seyedi; Fatemeh Abbasi-Feijani; Amirhossein Poopak; Houman Sotoudeh; Arash Kamali; Mohammad Hadi Aarabi
Journal:  Cerebellum       Date:  2022-01-10       Impact factor: 3.648

3.  Clinical Progression of Parkinson's Disease: Insights from the NINDS Common Data Elements.

Authors:  Mechelle M Lewis; Elias Harkins; Eun-Young Lee; Christy Stetter; Bethany Snyder; Tyler Corson; Guangwei Du; Lan Kong; Xuemei Huang
Journal:  J Parkinsons Dis       Date:  2020       Impact factor: 5.568

4.  Recent imaging advances in neurology.

Authors:  Lorenzo Rocchi; Flavia Niccolini; Marios Politis
Journal:  J Neurol       Date:  2015-03-26       Impact factor: 4.849

5.  The intrinsic resting state voice network in Parkinson's disease.

Authors:  Anneliese B New; Donald A Robin; Amy L Parkinson; Claudia R Eickhoff; Kathrin Reetz; Felix Hoffstaedter; Christian Mathys; Martin Sudmeyer; Christian Grefkes; Charles R Larson; Loraine O Ramig; Peter T Fox; Simon B Eickhoff
Journal:  Hum Brain Mapp       Date:  2015-01-27       Impact factor: 5.038

Review 6.  Current Clinical Applications of Diffusion-Tensor Imaging in Neurological Disorders.

Authors:  Woo Suk Tae; Byung Joo Ham; Sung Bom Pyun; Shin Hyuk Kang; Byung Jo Kim
Journal:  J Clin Neurol       Date:  2018-02-28       Impact factor: 3.077

Review 7.  Brain imaging of locomotion in neurological conditions.

Authors:  Gilles Allali; Helena M Blumen; Hervé Devanne; Elvira Pirondini; Arnaud Delval; Dimitri Van De Ville
Journal:  Neurophysiol Clin       Date:  2018-10-25       Impact factor: 3.734

8.  Chemical Exchange Saturation Transfer MR Imaging is Superior to Diffusion-Tensor Imaging in the Diagnosis and Severity Evaluation of Parkinson's Disease: A Study on Substantia Nigra and Striatum.

Authors:  Chunmei Li; Rui Wang; Haibo Chen; Wen Su; Shuhua Li; Xuna Zhao; Jinyuan Zhou; Jian Qiao; Baohui Lou; Guodong Song; Min Chen
Journal:  Front Aging Neurosci       Date:  2015-10-19       Impact factor: 5.750

9.  Microstructural Changes within the Basal Ganglia Differ between Parkinson Disease Subtypes.

Authors:  Lidia M Nagae; Justin M Honce; Jody Tanabe; Erika Shelton; Stefan H Sillau; Brian D Berman
Journal:  Front Neuroanat       Date:  2016-02-23       Impact factor: 3.856

10.  Is Diffusion Tensor Imaging a Good Biomarker for Early Parkinson's Disease?

Authors:  Rachel P Guimarães; Brunno M Campos; Thiago J de Rezende; Luiza Piovesana; Paula C Azevedo; Augusto C Amato-Filho; Fernando Cendes; Anelyssa D'Abreu
Journal:  Front Neurol       Date:  2018-08-21       Impact factor: 4.003

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.